Evidence map›Paper›PMID 26188639›Full record

ReviewCurrent treatment options in oncology2015

Surgical Options in the Treatment of Lower Gastrointestinal Tract Cancers.

Andrea S Porpiglia, Elin R Sigurdson

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Andrea S PorpigliaFox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA.
Elin R Sigurdson
Fox Chase Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer is the fourth most common cancer in the USA with the second highest mortality. Early detection with screening endoscopy, in addition to improvement in treatment modalities lead to higher overall survival rates. Treatment of localized colon cancer comprises of surgical resection with en bloc lymphadenectomy. Adjuvant therapy is determined by final pathologic stage. However, treatment of rectal cancer is more complex and is determined by the clinical pathologic stage. Neoadjuvant chemoradiation therapy is an important component to treatment to decrease the risk of local recurrence. As with colon cancer, adjuvant chemotherapy is dependent on the pathologic stage. Newer technologies are being utilized in both colon and rectal cancer including minimally invasive procedures and sphincter preservation procedures. Anal squamous cell carcinoma (SCC) is the most common histologic subtype of anal canal tumors. Anal SCC is most commonly seen in patients with HPV infections. Prior to the 1970s, anal SCC was treated with abdominoperineal resection and end colostomy. Nigro and colleagues utilized chemoradiation to treat anal SCC with response rates as high as 80%. This allows majority of patients to avoid an APR with permanent colostomy.

Indexed as

Early Detection of CancerAdenocarcinomaAnus NeoplasmsCarcinoma, Squamous CellChemotherapy, AdjuvantColonic NeoplasmsColostomyCombined Modality TherapyEndoscopy, GastrointestinalFecal IncontinenceHumansNeoplasm Recurrence, LocalNeoplasm StagingRadiotherapy, AdjuvantRectal NeoplasmsSurvival Rate

Identifiers

PMID26188639
OpenAlexW988430888

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.